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Apt105, 1600-7Myelopathy describes any neurologic deﬁcit related to the spinal cord. It is most commonly
caused by its compression by neoplasms, degenerative disc disease, trauma, or infection.
Less common causes of myelopathy include spinal cord tumors, infection, inﬂammatory,
neurodegenerative, vascular, toxic, and metabolic disorders. Conditions affecting the spinal
cord must be recognized as early as possible to prevent progression that may lead to
permanent disability. Biopsy is rarely performed, thus the diagnosis and management rely on
patient 's history, physical examination, laboratory results, and imaging ﬁndings. Here we
review the clinical presentations, pathophysiological mechanisms, and magnetic resonance
imaging ﬁndings of myelopathies related to metabolic or toxic etiologies.
Semin Ultrasound CT MRI 37:448-465 C 2016 Elsevier Inc. All rights reserved.Introduction
Myelopathy is a term used to describe neurologic deﬁcitsrelated to the spinal cord. It is usually compressive in
nature, typically associated with neoplasm, degenerative dis-
ease, trauma, or infection, whichmay bemanaged surgically to
relieve the cord compression in hopes of restoring normal
function. Less common noncompressivemyelopathies include
inﬂammatory etiologies such as autoimmune, demyelinating,
paraneoplastic, or infectious diseases and noninﬂammatory
myelopathies, such as metabolic, toxic, or vascular disorders,
which may not be amenable to surgical intervention and
require different approaches to diagnosis and treatment.
Toxic and metabolic myelopathies may be further subdi-
vided into (1) metabolic myelopathies associated with an
identiﬁed nutrient deﬁciency including cobalamin or B12
vitamin, folate, copper, or vitamin E deﬁciencies; (2) toxic
myelopathies associated with drugs and chemical agents such
as heroin abuse, organophosphate poisoning, chemotherapeu-
tic agents, and radiation therapy; (3) metabolic myelopathies
with geographical predilection such as lathyrism and Konzo
seen in India, Bangladesh, and Ethiopia and, (4) other rareg/10.1053/j.sult.2016.05.010
016 Elsevier Inc. All rights reserved.
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ketoacidosis myelopathy, spinal cord decompression illness,
and surfer 's myelopathy (Table 1). Toxic and metabolic
myelopathies share clinical, electrophysiological, neuropatho-
logic, and imaging features. Variable degrees of peripheral
nerve and optic nerve involvement are present and usually
known as a myeloneuropathy and preferential involvement
of the dorsal columns and corticospinal tracts is seen. Our
purpose is to review the uncommon toxic and metabolic
myelopathies giving special emphasis to their clinical
presentation, pathophysiological mechanisms and magnetic
resonance imaging (MRI) ﬁndings.Myelopathies Associated With
Nutrient Deﬁciencies
Cobalamin or B12 Vitamin Deﬁciencies
Deﬁnition
Vitamin B12 deﬁciency causes myelopathy, neuropathy, and
neuropsychiatric disturbances. In the spinal cord, it manifests
as a subacute combined degeneration, characterized by degen-
eration of the lateral and posterior columns. It is considered the
most common metabolic myelopathy.1-3
Pathophysiology
Vitamin B12 deﬁciency is due to inadequate intake and
malabsorption. Inadequate intake is seen in strict vegetarians
and is considered rare in the Western World. Pernicious
anemia (the most common cause in the West), gastrectomy,italar Lisboa Central September 16, 2016.
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Table 1 Toxic and Metabolic Myelopathies
Key Findings*
Myelopathies associated with nutrient deﬁciency
Cobalamin or B12 vitamin deﬁciency Subacute combined degeneration, peripheral neuropathy and neuropsychiatric
disturbances. Megaloblastic anemia may be present.
Nitrous oxide toxicity (associated with
B12 inactivation)
Previous exposure to N2O (“anesthesia paresthetica”).
Folate deﬁciency Similar to B12 vitamin deﬁciency.
Copper deﬁciency Subacute combined degeneration and history of gastric surgery.
Vitamin E deﬁciency Progressive spinocerebellar syndrome with lesions in the posterior columns on MRI.
AIDS-associated myelopathy
(mechanism not completely
understood)
Patients who are HIV positive presenting with lesions in the posterior columns
predominantly in the upper thoracic cord on MRI.
Toxic myelopathies associated with drugs and chemical agents
Heroin myelopathy Progressive involvement with selective involvement of the ventral pons and lateral and
posterior columns of the spinal cord.
Hepatic myelopathy Pure motor spastic paraparesis with involvement of the lateral corticospinal tracts.
Evidence of manganese deposition in the basal ganglia (high signal on T1-WI) is
common.
Organophosphate poisoning Delayed myelopathy and neuropathy presenting with spinal cord atrophy that persists
long after the cholinergic effects of organophosphate had subsided.
Chemotherapy and radiation therapy-
related myelopathies
History of chemotherapy and radiation therapy. The affected spinal cord segment is in
the same area as the radiation-induced bone marrow changes.
Toxic myelopathies with geographical predilection
Spinal sea stroke Spinal cord infarct in patients swimming in the sea of speciﬁc locations in the globe.
Subacute myelo-optico neuropathy
(clioquinol toxicity)
Subacute myelo-optic neuropathy after clioquinol treatment.
Lathyrism (seen in India, Bangladesh,
and Ethiopia) and Konzo (Africa)
Speciﬁc dietary habits.
Other noninfectious and noninﬂammatory myelopathies
Ketoacidosis myelopathy Rare complication of diabetic ketoacidosis.
Spinal cord decompression illness Patients diagnosed with decompression sickness presenting with patchy areas of
increased T2 signal intensity in the spinal cord with no segmental distribution.
Surfer 's myelopathy Longitudinally extensive T2 hyperintense central cord lesion in the midthoracic region
in novice surfers.
*All listed entities cause a very similar pattern of clinical and imaging involvement of the posterior and lateral columns.
Toxic and metabolic myelopathies 449intestinal infections and ileal abnormalities (Helicobacter
pylori, Diphyllobothrium latum, human immunodeﬁciency
virus, intestinal tuberculosis or lymphoma, celiac disease,
Whipple’s disease, inﬂammatory bowel disease, radiation
enteritis, graft-versus-host disease, pancreatic disease, Zollinger-
Ellison syndrome, and tropical sprue, bacterial over-
growth) lead to malabsorption1,4. Other conditions include
elderly (related to atrophic gastritis-related hypochlorhydria
induced food-Vitamin B12 malabsorption), hereditary enzy-
matic defects and mutations in genes encoding endocytic
receptors involved in ileal absorption and cellular Cbl
uptake (Mutations in CUBN and AMN (selective Cbl
malabsorption and proteinuria: Imerslund-Gras̈beck
syndrome), mutations in gastric intrinsic factor (GIF) or
TCN2 (transcobalamin) leading to absence of the protein
or presence of abnormal protein, disorders of intracellular
processing and utilization of vitamin B12, disorders
involving the synthesis of cobalamin cofactors (cblA to
cblG), and medications (Antacids, H2 blockers, metformin,
sunitinib).1Downloaded from ClinicalKey.com at Centro Hos
For personal use only. No other uses without permission. CCoenzyme vitamin B12 (cobalamin), which together with
folate, is essential for the formation of methionine from
homocysteine tetrahydrofolate. It is absorbed in the ileal
microvilli after binding to the intrinsic factor. Tetrahydrofolate
is necessary for normal DNA synthesis and methionine is
converted to S-adenosylmethionine that is necessary for
methylation of myelin sheath phospholipids. B12 deﬁciency
results in decreased activity of cobalamin-dependent methyl-
cobalamin esterase enzyme with resultant elevation of meth-
ylmalonic acid and reduced myelin basic protein methylation
with fragile myelin that is susceptible to demyelination and
vacuolization.1,4
Clinical Presentations
Vitamin B12 deﬁciency may lead to serious neurologic com-
plications including neuropathy, myelopathy, neuropsychiat-
ric disturbances, and optic neuropathy. These may be
accompanied by hematologic manifestations of cobalamin
deﬁciency such as anemia, macrocytosis, neutrophil hyper-
segmentation, or megaloblastic marrow changes. Subacutepitalar Lisboa Central September 16, 2016.
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Table 2 Clinical Manifestations of Vitamin B12 Deﬁciency
*
Neurologic manifestations (may be the earliest and often the only manifestation of B12 deﬁciency)
Myelopathy (subacute combined degeneration)
Numbness, weakness, and paresthesia of the extremities that primarily affect the lower extremities, often symmetric, and
progresses in a distal-to-proximal manner. Later this myelopathy progresses to unsteady gait, poor coordination, sensory
deﬁcits, and bowel or bladder dysfunctions
Physical examination: signs of dorsal column involvement include loss of position and vibration sense or ataxia. Lateral column
involvement includes spasticity, hyperreﬂexia, and positive Babinski sign. Involvement of the spinothalamic tracts with sensory
level may also be present
Peripheral neuropathy and optic neuropathy may be seen
Psychiatric manifestations
Cognitive impairment
Personality and mood changes with depression and psychosis
Hematologic manifestations
Megaloblastic anemia or megaloblastic marrow changes
Pancytopenia (leukopenia and thrombocytopenia)
*Adapted from Kumar.1
J. Ramalho et al.450combined degeneration presents as a myelopathy (clinical
manifestations are summarized in Table 2).1
Pathology Findings
Neuropathologic ﬁndings initially include swelling of myelin
sheaths with little change in axons in the posterior columns of
the upper cervical segments (funiculus gracilis and spinocer-
ebellar tracts) and in the lateral columns, which typically
commence in the upper thoracic cord but can extend to
involve other levels. Later, myelin sheath and axonal degener-
ation and loss are seen leading to Wallerian-type degeneration
of the long tracts which may extend symmetrically in the
cranial-caudal direction. Other sites of involvement include
peripheral nerves, cerebrum, and optic nerves.4
Imaging Findings
MRI shows increased signal intensity in the posterior and
lateral white matter columns of spinal cord on T2-weighted
images (T2-WI) (Fig. 1). The “inverted V” or “inverted rabbit
ears” signs are often present and described as symmetrical T2
hyperintensities in the lateral aspects of the dorsal columns
(Fig. 2).5 Cervical and upper thoracic cord aremost commonly
and severely affected as a continuous long segment.2,4,6,7 Mild
cord expansion and contrast enhancement may be seen.8
Spinal cord lesions may resolve after appropriate therapy,
however cord atrophy develops in some patients.9 Rarely,
diffuse white matter abnormalities (supratentorial and infra-
tentorial) suggestive of a leukoencephalopathy, particularly
affecting the corticospinal tracts, may be seen.10,11
Diagnosis
Diagnosis is conﬁrmed by low serum B12 or if the B12 is
borderlined by elevated homocysteine and methylmalonic
acid. Hematological changes such as megaloblastic anemia
are not reliable markers of the disease.1
Treatment or Prognosis
Treatment goals are to reverse the signs and symptoms of
deﬁciency, replete body stores, ascertain the cause of theDownloaded from ClinicalKey.com at Centro Hos
For personal use only. No other uses without permission. Cdeﬁciency and monitor response to therapy. Severe impaired
absorption requires parenteral therapy and most common
recommended treatment is with B12 intramuscular injections
continued monthly for life. Spine and brain MRI ﬁndings may
resolve within a few months after starting therapy and the
degree of recovery is inversely proportional to symptom
duration and severity. Therefore, early diagnosis leads to full
recovery.1Nitrous Oxide Toxicity
Deﬁnition
Nitrous oxide (N2O or “laughing gas”) is a commonly used
inhalational anesthetic that causes irreversible inactivation of
vitamin B12 by oxidation and has been associated with a
myeloneuropathy resembling subacute combined degenera-
tion seen with B12 deﬁciency.
1,5
Pathophysiology
Methylcobalamine, the active form of intracellular vitamin B12,
is required by the methionine synthetase enzyme to con-
vert homocysteine into methionine and methyltetrahydrofo-
late into tetrahydrofolate. N2O inactivates vitamin B12 by
irreversible oxidation of the cobalt center of methylcobalamine
from the monovalent to bivalent and trivalent forms. The
methionine synthesis pathway is thereby inhibited. In nor-
mal subjects, blocking of methionine synthesis by N2O does
not cause symptoms. However, subclinical vitamin B12-
deﬁcient individuals are prone to neurologic degeneration
because N2O causes exhaustion of the residual stocks of
vitamin B12
1,12
Clinical Presentations
Myeloneuropathy results from chronic exposure or after a
single exposure in individuals with B12 deﬁciency. Signs and
symptoms appear rapidly with N2O toxicity and may be seen
despite a normal serum B12 level. Less commonly, symptoms
may be delayed up to 2 months after acute exposure. Neuro-
logic manifestations may include a myelopathy (subacutepitalar Lisboa Central September 16, 2016.
opyright ©2016. Elsevier Inc. All rights reserved.
A B
Figure 1 Vitamin B12 deﬁciency. Axial (A) T2-WI in a patient with vitamin B12 deﬁciency shows high-signal intensity
involving the dorsal (dashed arrow) and lateral columns (white arrows), also seen on sagittal T2-WI (B) (arrows).
Toxic and metabolic myelopathies 451combined degeneration), neuropathy, myeloneuropathy, and
mental status changes.1,12Pathology Findings
Neuropathologically, the ﬁndings are similar to Vitamin B12
related subacute spinal degeneration which are characterized
by reversible swelling of myelin sheaths in the posterior and
lateral columns. Later, myelin sheath and axonal degeneration
are seen leading to irreversible Wallerian-type degeneration of
the long tracts.12Imaging Findings
MRI typically shows high T2 signal intensity in the posterior
columns (sometimes in the lateral and anterior columns) of the
cervical or thoracic spinal cord with often several vertebral
bodies in length (Fig. 3). Modest expansion of the spinal cordA B
Figure 2 Vitamin B12 deﬁciency. Axial (A and B) and sagittal (C) T
signal intensity involving the dorsal columns (arrows). Note typ
Downloaded from ClinicalKey.com at Centro Hos
For personal use only. No other uses without permission. Cmay be seen. Contrast enhancement is rare and generally mild
when it present.9,12,13
Diagnosis
The diagnosis of myeloneuropathy because of N2O is a clinical
one and should be considered in patients who develop
neurologic symptoms following surgical and dental proce-
dures (“anesthesia paresthetica”) or in recreational users.1,12
Treatment or Prognosis
Prevention includes prophylactic administration of vitamin B12
weeks before surgery in individuals with a borderline vitamin
serum level who receives N2O anesthesia.
1 Treatment involves
high doses of vitamin B12. Administration of methionine may
also be required. Exogenous methionine provides a direct
substrate for methionine synthetase whereas the body slowly
replaces the inactive vitamin B12 and starts repletion ofC
2-WI in a patient with vitamin B12 deﬁciency show high-
ical “inverted V” or “inverted rabbit ears” on axial images.
pitalar Lisboa Central September 16, 2016.
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A B C
Figure 3 Nitrous oxide toxicity. Axial (A and B) and sagittal (C) T2-WI of the cervical spine in a patient with myelopathy
after surgerywith nitrous oxide anesthesia. Imagingﬁndings are typical of vitamin B12 deﬁciencymyelopathywith highT2-
WI signal involving the dorsal columns (arrows). This patient had undiagnosed B12 deﬁciency and nitrous oxide
administration resulted in subacute combine degeneration.
J. Ramalho et al.452endogenous methionine. Improvement of symptoms andMRI
changes are seen after replacement therapy is started.12Folate Deﬁciency
Deﬁnition
Folate deﬁciency rarely exists in a pure state and is often
associatedwith conditions that affect other nutrients. Themost
common manifestation of folate deﬁciency is a myelopathy or
myeloneuropathy resembling subacute combined degenera-
tion seen with B12 deﬁciency.
1
Pathophysiology
Folate is a water-soluble B vitamin present in fresh green
vegetables, citrus fruits, legumes, and liver. As with B12, folate
acts as an important cofactor in DNA synthesis and methyl-
ation pathways. Its deﬁciency results from reduced intake of
folate-rich products, impaired absorption, or increased folate
metabolism. It is associated with alcoholism, small bowel
disorders, and drugs such as methotrexate and trimethoprim.
Folate absorption may be decreased with reduced gastric
secretions in patients after gastric surgery, atrophic gastritis,
acid-suppressive therapy, and acid neutralization by treatment
of pancreatic insufﬁciency.1,14
Clinical Presentations
Folate deﬁciency causes similar manifestations to those of
vitamin B12 deﬁciency because of its importance in production
of methionine and tetrahydrofolate. For unclear reasons,
neurologic and hematologic manifestations due to folate
deﬁciency are rare, mild, and confounding. Neurologic man-
ifestations of folate deﬁciency include amyelopathy, peripheral
neuropathy, optic neuropathy, and cognitive or behavioral
manifestations.1,14
Pathology Findings
Pathologically, folate deﬁciency myelopathy is identical to
vitamin B12 deﬁciency myelopathy and characterized by
reversible swelling of myelin sheaths in the posterior and
lateral columns.1,4,10,14Downloaded from ClinicalKey.com at Centro Hos
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Subacute combined degeneration due to folate deﬁciency
resembles other forms of subacute combined degeneration
(Fig. 4).1,4,9,14
Diagnosis
Attribution of neurologic manifestations to pure folate deﬁ-
ciency requires exclusion of other causes. Serum folate levels
between 2.5 and 5 μg/L may be indicative of a mildly
compromised folate status. Erythrocyte folate is more reliable
than plasma folate because its levels are less affected by short-
term ﬂuctuations in intake. Plasma homocysteine levels are
typically elevated in patients with clinically signiﬁcant folate
deﬁciency.1,14
Treatment or Prognosis
Daily doses, as high as 20 mg, may be necessary in patients
with malabsorption. Reduced folates are required only when
folatemetabolism is impaired by drugs such asmethotrexate or
inborn errors of metabolism. Plasma homocysteine is best for
monitoring response to therapy as it decreases within a few
days of instituting folate therapy but does not respond to
inappropriate vitamin B12 therapy.
1,14Copper Deﬁciency
Deﬁnition
Acquired copper deﬁciency may cause myelopathy or
myeloneuropathy that resembles subacute combined
degeneration.1,15
Pathophysiology
Copper permits electron transfer in key enzymatic pathways. It
is a component of metalloenzymes, including cytochrome-c
oxidase, that have a critical role in the structure and function of
the nervous system. Reduction in cytochrome-c oxidase
activity may be the basis for neurologic dysfunction in copper
deﬁciency.16 Because of copper 's ubiquitous distribution and
low daily requirement, acquired dietary copper deﬁciency is
rare. The coexistence of multiple causes of copper deﬁciencypitalar Lisboa Central September 16, 2016.
opyright ©2016. Elsevier Inc. All rights reserved.
A B
Figure 4 Folate deﬁciency. Axial (A) and sagittal (B) T2-WI in a patient with folate deﬁciency show high-signal intensity
involving the dorsal columns (arrows).
Toxic and metabolic myelopathies 453increases the chances of development of a clinically deﬁciency
state. Themost common cause of acquired copper deﬁciency is
a history of gastric surgery. Typically, neurologic manifesta-
tions are delayed by years following gastric surgery. Excessive
zinc ingestion is also a recognized cause of copper deﬁciency.
Additionally, copper deﬁciency has been reported in entero-
pathies associated with malabsorption such as cystic ﬁbrosis,
sprue, bacterial overgrowth, and inﬂammatory bowel disease.1Clinical Presentations
Neurologic manifestations are similar to those seen with B12
deﬁciency with which they may coexist. The most common
manifestation is that of a myelopathy presenting with a spastic
gait and prominent sensory ataxia because of dorsal column
dysfunction. Central nervous system (CNS) demyelination,
peripheral neuropathy, and optic neuritis also occur.1,16Pathology Findings
Copper deﬁciency–associated myelopathy has been well
described in animal models. The typical distribution of spinal
cord lesions is that of greater involvement of the cervical cord
with less severe changes in the thoracic and lumbar segments.
Wallerian degeneration and demyelination with microcavita-
tion of thewhitematter of the spinal cord, particularly affecting
the dorsal columns and brainstem, are typical.16Imaging Findings
The most common abnormality on the spine MRI is increased
T2-WI signal in the dorsal columns, mostly in the cervical
cord; contrast enhancement is not seen (Fig. 5). Additionally,
signal changes involving the lateral columns and extension of
the pyramidal tract signal changes into the brainstem have
been reported. These ﬁndings are similar to those seen in
patients with vitamin B12 deﬁciency.
1,15-18Downloaded from ClinicalKey.com at Centro Hos
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Laboratory indicators of copper deﬁciency include a decrease
in serum copper or ceruloplasmin and in 24-hour urinary
copper excretion. Changes in serum copper usually parallel
ceruloplasmin concentration. Serum zinc and 24-hour urinary
zinc excretion levels should be obtained and an elevation in
these should prompt an aggressive search for an exogenous
source of zinc.1,16Treatment or Prognosis
Oral copper supplement is the method of supplementation.
Response of hematological parameters (including bone mar-
row ﬁndings) is prompt and often complete. Recovery of
neurologic signs and symptoms is variable. In patients in
whom excess zinc ingestion is the cause, stopping zinc
supplements may sufﬁce and no additional copper supple-
ments may be required.1,15,18Vitamin E Deﬁciency
Deﬁnition
Vitamin E deﬁciencymanifests as a progressive spinocerebellar
syndrome.Pathophysiology
Vitamin E is as a fat-soluble antioxidant preventing peroxida-
tion of membrane fatty acids. Most vitamin E in the human
body is localized in adipose tissues. More than 2 years are
required for adipose tissues to reach steady-state levels in
response to changes in dietary intake. In adults, vitamin E
deﬁciency is most often associated with fat malabsorption
syndromes (celiac disease, cystic ﬁbrosis, and cholestasis) and
other intestinal disorders. In children, vitamin E deﬁciency
may be seen because of genetic in alphatocopherol transfer
protein, abetalipoproteinemia, or defects in chylomicron syn-
thesis and secretion.1pitalar Lisboa Central September 16, 2016.
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A B
Figure 5 Copper deﬁciency. (A and B) Axial T2-WI at C1-2 level in a patient with Cu deﬁciency demonstrate high-signal
intensity involving dorsal columns (arrows).
J. Ramalho et al.454Clinical Presentations
Neurologic manifestations of vitamin E deﬁciency include a
progressive spinocerebellar syndrome, similar to those of
Friedreich ataxia, and a peripheral neuropathy with gait
difﬁculty, hyporeﬂexia or areﬂexia, pyramidal signs, impaired
position and vibration perception, and dysarthria. Pigmented
retinopathy, myopathy, movement disorders, and gaze palsies
have also been reported.1,19
Pathology Findings
Lesions in the dorsal root ganglia, posterior medullary tracts,
cerebellar cortex, spinocerebellar tracts, anterior horn cells, and
peripheral nerves have been reported.20
Imaging Findings
MRI may show high-signal lesions on T2-WI in the posterior
columns. Cerebellar atrophy may be present.21,22
Diagnosis
Serum vitamin E levels are dependent on concentrations of
serum lipids. Hyperlipidemia or hypolipidemia can increase or
decrease serum vitamin E without reﬂecting similar alterations
in tissue levels. Effective serum vitamin E levels are calculated
by dividing the serum vitamin E by the sum of serum
cholesterol and triglycerides. In patients with neurologic
manifestations serum vitamin E levels are frequently
undetectable.1
Treatment or Prognosis
Replacement of vitamin E is treatment of choice. Improvement
of neurologic symptoms or signs in severe cases may not
occur.1
AIDS-Associated Myelopathy
Deﬁnition
AIDS-associated myelopathy, also called vacuolar myelopathy,
is a spinal cord disease in human immunodeﬁciency virus
(HIV) positive patients. Clinical manifestations, imaging ﬁnd-
ings, and histopathology resemble that of subacute combined
degeneration because of vitamin B12 deﬁciency. It may occur at
any stage during the course of HIV infection but is more
commonwith advanced immunosuppression. Reliable data on
the incidence and prevalence of myelopathy in HIV patients
are not available.1,23Downloaded from ClinicalKey.com at Centro Hos
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The cause of vacuolar myelopathy is unknown. Increased
prevalence of B12 deﬁciency occurs in HIV patients with
neurologic symptoms but its signiﬁcance is unclear. Impair-
ment in methylation pathways related or not to viral infection
of the spinal cord have been proposed.1,23,24Clinical Presentations
Manifestations of vacuolar myelopathy are varied and often
include painless spastic paraparesis that is slowly progressive
with a sensory ataxia. There may be an associated sphincter
and erectile dysfunctions. Overlapping peripheral neuropathy
may confound the diagnosis. Hyperreﬂexia at the knees with
reduced ankle reﬂexes are common.23Pathology Findings
Vacuolar myelopathy is characterized by intralamellar vacuo-
lation in the spinal white matter throughout the lateral and
posterior columns of the thoracic and cervical segments.23,25Imaging Findings
MRI features of vacuolar myelopathy include high T2 intensity
lesions in the posterior columns predominantly in the
upper thoracic cord. Frequently, the spinal cord may be
normal or show atrophy and nonspeciﬁc patchy T2-WI
abnormalities.23,25Diagnosis
Diagnosis is made by exclusion by ruling out vitamin B12
deﬁciency, human T-lymphotrophic virus-1, and neurosyphi-
lis. Cerebrospinal ﬂuid (CSF) may be normal or show mild
pleocytosis with mild protein elevation. Similar ﬁndings may
be seen in asymptomatic HIV patients.Treatment or Prognosis
There is no effective therapy for HIV-associated myelopathy.
The role of antiretroviral therapy is not established, however
following antiretroviral therapy MRI may show signiﬁcant
reduction of the T2 hyperintensity of the posterior
columns.23,25pitalar Lisboa Central September 16, 2016.
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Toxic and metabolic myelopathies 455Toxic Myelopathies Associated
With Drugs and Chemical Agents
Heroin Myelopathy
Deﬁnition
Myelopathy induced by heroin is progressive with selective
involvement of the ventral pons and lateral and posterior
columns of the spinal cord and may be associated with
inhalation (“chasing the dragon”) or intravenous use.1,26,27
Pathophysiology
Proposed mechanisms include direct toxicity, vasculitis, or
hypersensitivity reaction. Isolated toxicity seems less probable
as systemic toxins typically involve the nervous system more
diffusely along with other organs. Generalized vasculitis would
be unlikely to ﬁrst affect the spinal cord.27 Thus, hyper-
sensitivity is the predominant explanation as the myelopathy
may occur after a period of abstinence followed by a single
use.1,26-30 Hypotension may possibly result in border-zone
infarctions in the cord.1 However, hypotension is unlikely to
be severe enough to damage the spinal cord and spare the
more ischemia-sensitive neurons of the brain. Furthermore,
although the level of injury varies among reported cases, no
pattern ﬁtting the vascular “watershed zones” of the spinal cord
has been documented.27
Clinical Presentations
Clinical picture consists of an initial ﬂaccid paraparesis or
paraplegia of sudden onset with sensory loss in the legs and
lower thoracic dermatomes and urinary sphincter disturban-
ces. Occasionally the sensory and motor levels extend to the
cervical region,31 resembling symptoms of transverse myelitis.
Pathology Findings
Extensive necrosis of the cervical and thoracic cord has been
described in some patients.31
Imaging Findings
MRI is frequently normal. Hyperintense lesions on T2-WI and
ﬂuid attenuation inversion recovery (FLAIR) images affecting
the posterior and lateral columns, pontomedullary region, and
ventral pons may be seen. Findings consistent with acute
transverse myelitis have also been reported. Contrast enhance-
ment is variable and usually patchy.27
Diagnosis
Most reports describe normal CSF ﬁndings although pleocy-
tosis and increased total protein may occur.28-30,32
Treatment or Prognosis
Treatment with either intravenous corticosteroids or immu-
nopheresis may limit immune response preventing disability
but their efﬁcacy requires further validation.27 Prognosis is
often poor, with residual spastic paraparesis and sensory
deﬁcits, and in some patients death.29 Full recovery has been
reported occasionally.31Downloaded from ClinicalKey.com at Centro Hos
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Deﬁnition
Hepatic myelopathy or portosystemic myelopathy is a rare
neurologic complication of chronic liver disease with portal
hypertension usually associated with portosystemic shunting
either surgically created or spontaneous. It is characterized by
an insidious onset of pure motor spastic paraparesis without
sensory or sphincter involvement.33
Pathophysiology
Pathophysiology is poorly understood and it is broadly
accepted that nitrogenous products such as ammonia, fatty
acids, indoles, and mercaptans bypassing the liver through a
portocaval shunt play an important role.34 These metabolites
cause myelin damage resulting in demyelination in the brain
and spinal cord. Selective predisposition of the motor system
has been demonstrated by involvement of the lateral cortico-
spinal tracts in autopsy studies. Other causative factors include
nutrient deﬁciencies and deranged liver metabolism.33 Addi-
tionally, the myelopathy may also be related to elevated
manganese levels with MRI evidence of manganese deposition
in the basal ganglia without extrapyramidal manifestations or
clinical evidence of decompensated cirrhosis.1,26,35
Clinical Presentations
The typical clinical presentation is a progressive pure motor
spastic paraparesis with minimal or no sensory deﬁcits and no
bowel or bladder involvement. Most patients report prior
episodes of hepatic encephalopathy andoften the development
ofmyelopathy follow the creation of surgical shunts. However,
preceding portosystemic encephalopathy is not invariably
present.1 Early and accurate diagnosis is important because
patients with early stages of the disease can recover following
liver transplantation.33,36
Pathology Findings
Neuropathologic studies show demyelination in the lateral
corticospinal tracts with varying degrees of axonal loss.33,37
Imaging Findings
MRI usually shows symmetric high T2 signal intensity in the
lateral corticospinal tracts and less commonly in the ventral
pyramidal tracts, posterior columns, and spinocerebellar
tracts.36 Increased pallidal T1 signal in presence of elevated
serum manganese may also be present.
Diagnosis
Hepatic myelopathy is diagnosis of exclusion. Motor evoked
potential studies may be suitable for the early diagnosis even in
patients in the preclinical stages of the disease.33,38
Treatment or Prognosis
Hepatic myelopathy is a rare and debilitating disorder with no
effective treatment. However, its early identiﬁcation and
exclusion of other treatable causes is important. Some patients
improve following liver transplantation26 but the therapeutic
potential of liver transplantation for preventing progression
and allowing recovery needs to be further validated.33pitalar Lisboa Central September 16, 2016.
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J. Ramalho et al.456Organophosphate Poisoning
Deﬁnition
The most common complication of organophosphate poison-
ing is an acute intoxication with a cholinergic crisis because of
the inhibition of acetylcholinesterase. Some patients subse-
quently develop organophosphate-induced delayed myelop-
athy andneuropathy, also known as organophosphate-induced
delayed neurotoxicity (OPIDN).Pathophysiology
Organophosphates are common components of pesticides
available in many homes. A major chemical that causes
symptoms is triorthocresyl phosphate. Signs and symptoms
of acute organophosphate toxicity are because of acetylcholi-
nesterase inhibition and resulting muscarinic and nicotinic
dysfunctions. In the neuromuscular junction, acetylcholine is
released when a nerve impulse reaches terminal axonal end
and it diffuses across the synaptic cleft and binds to cholinergic
nicotinic receptors on the muscle ﬁbers, causing them to
contract. The enzyme, cholinesterase splits acetylcholine into
acetic acid and choline, stopping its action. Endproducts of the
metabolism of acetylcholine are taken up by nerve ﬁbers and
resynthesized into acetylcholine. In organophosphate poison-
ing, cholinesterases are phosphorylated by the phosphate end
of organophosphates resulting in excessive accumulation of
acetyl chlorine with resultant effects on muscarinic, nicotinic
receptors in the CNS.39 After resolution of a cholinergic crisis,
an intermediate syndrome can develop in some patients. It is
likely a neuromuscular junction defect syndrome.40 OPIDN is
a late complication of some organophosphorus compounds
and is possibly because of phosphorylation and subsequent
aging of neurotoxic esterase in the nervous system.1,41Clinical Presentations
After organophosphate poisoning, 3 well-deﬁned clinical
phases may be seen as follows: an initial acute cholinergic
crisis, an intermediate syndrome, and OPIDPN. Pinpoint
pupils, excessive salivation, generalized weakness, and respi-
ratory collapse characterize the acute cholinergic crisis. The
intermediate syndrome is characterized by weakness of neck
ﬂexors, proximal limbs, and respiratory muscles. OPIDN
occurs 1-3 weeks after acute exposure and following an
uncertain duration after chronic exposure. OPIDN may occur
in absence of the cholinergic or intermediate phase. Symptoms
include distal paresthesias, progressive leg weakness and
wasting, and cramping muscle pain. There may be evidence
of upper limb involvement and pyramidal tract dysfunction.
Sensory loss when present is mild.1Pathology Findings
Studies in chicks with organophosphate-induced delayed
neuropathy show severe damage in the ventral and lateral
tracts of the thoracic spinal cord. The same neuropathologic
changes may be associated with prominent and diffuse spinal
cord atrophy especially in the thoracic region.42Downloaded from ClinicalKey.com at Centro Hos
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MRI at the late phase of exposuremay reveal evidence of spinal
cord atrophy that persists long after the cholinergic effects had
subsided.
Diagnosis
There is usually a delay in onset of clinical symptoms after
exposure to organophosphates.Measurement of cholinesterase
activity in red blood cells helps conﬁrm the diagnosis because
red blood cells cholinesterase activity is less rapidly depressed
than serum cholinesterase activity.1,26,43 In the late phase
somatosensory evoked potentials are often abnormal.
Treatment or Prognosis
Acute symptoms are best treated with pralidoxime and
atropine. Pralidoxime is a reactivator of inhibited acetylcholi-
nesterase and is its speciﬁc antidote.1Chemotherapy-Related Myelopathies
Deﬁnition
Acute myelopathy is a rare but devastating complication of
chemotherapy treatment. It has been reported following
administration of different chemotherapeutic agents including
methotrexate, cytarabine, cisplatin, cladarabine, doxorubicin,
vincristine, and cytosine arabinoside.26
Pathophysiology
Intrathecal methotrexate and cytarabine are the most fre-
quently implicated agents.44 Acute or chronic leukoencephal-
opathy is the most common type of methotrexate-induced
neurotoxicity and subacute myelopathy is rare.45 The patho-
genesis of methotrexate-induced myelopathy is not clear but it
is probablymultifactorial; Following 2majormechanismshave
been proposed: indirect inhibition ofmethionine synthesis and
direct toxicity. Methotrexate inhibits the enzyme dihydrofolate
reductase and prevents folic acid from converting to tetrahy-
drofolic acid causing folate deﬁciency. This deﬁciency indi-
rectly inhibits the synthesis of methionine, as folate is an
important cofactor in DNA synthesis and methylation path-
ways. As methionine is necessary for formation and main-
tenance of myelin sheaths, its deﬁciency may lead to vacuolar
degeneration ofwhitematter. Thismechanism is similar to that
of subacute combined degeneration of the spinal cord because
of vitamin B12 deﬁciency. A constitutional predisposition or
abnormal sensitivity to methotrexate such as genetic poly-
morphisms or mutations related to methionine metabolism
may also play a role in the pathogenesis as the reported
frequency of severe methotrexate myelopathy is dispropor-
tionately low considering the large number of patients receiv-
ing the drug intrathecally.46 Another proposed mechanism is
direct injury of endothelial cells in venules and capillaries of the
spinal cord with blood-brain barrier disruption, increased
vascular permeability, and insinuation of plasma proteins into
the vascular walls46 which lead to their degeneration and
necrosis and vacuolar degeneration of white matter. Vascular
injury also allows the drug to diffuse into the CNS causing
direct toxic effects. Direct toxic effect of intrathecalpitalar Lisboa Central September 16, 2016.
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Toxic and metabolic myelopathies 457administration of methotrexate on the pia mater and white
matter is probably caused by pia-glial barrier disruption and
myelin sheaths and oligodendrocytes injuries.46
Known risk factors for development of methotrexate
myelopathy include the following: cumulative intrathecal
doses and continuous exposure to the drug more than a
prolonged period of time, systemic administration, concurrent
radiotherapy, and CNS involvement by the primary disease.47
Clinical Presentations
There is a variable clinical course in regard to time and rate of
onset after therapy, severity of disease, and degree of recov-
ery.48 Overall, 2 clinical patterns of paraparesis have been
described.49 A transient, ﬂaccid, and areﬂexic paraparesis with
pain and anesthesia may occur soon after intrathecal injection.
Rarely, the paralysis may ascend with respiratory compromise
and death. A less common form is a progressive spastic-ataxic
paraparesis with sphincter dysfunction seen after weeks of a
series of intrathecal treatments.1 The latency to onset of
symptoms is variable and can be long.
Pathology Findings
Reports on the neuropathologic ﬁndings of methotrexate-
induced myelopathy are rare and ﬁndings vary from vacuolar
degeneration of the lateral andposterior columns in association
with severe loss of axons and myelin sheaths to complete
transverse necrosis of the spinal cord or a combination of
both.46 The gray matter is relatively spared.46
Imaging Findings
MRI ﬁndings are nonspeciﬁc and the initial imaging examina-
tion is often normal. Symmetric increased T2 signal in dorsal
and lateral columns of the cord without abnormal contrast
enhancement similar to that of subacute combine degeneration
has been described (Fig. 6). Cord swelling and contrast
enhancement have also been reported. Long-term outcome
is generally that of cord atrophywithnormal T2 signal intensity
demonstrated as early as 6 months after clinical onset of
disease.48,50
Diagnosis
Chemotherapy-induced myelopathy is a diagnosis of exclu-
sion. The main differential diagnosis includes malignancy,
viruses, radiation, and paraneoplastic myelopathy.48
Treatment or Prognosis
Chemotherapy-induced myelopathy carries a poor prognosis.
Preservative-containing chemotherapeutic agents or diluents
should not be used intrathecally49 and multiple and frequent
intrathecal therapy should be avoided.1 Meticulous neurologic
monitoring of methotrexate concentration in CSF is important
to prevent the occurrence of this complication.46 Immediate
discontinuation of intrathecal methotrexate treatment
and supplementation of derivates of folic acid and methio-
nine or homocysteine metabolic pathway, such as
S-adenosylmethionine and cyanocobalamine, are the best
treatment options.51 However, further research is required to
establish an effective and deﬁnite treatment.45Downloaded from ClinicalKey.com at Centro Hos
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Deﬁnition
Radiation myelopathy is deﬁned as injury caused by ionizing
radiation.52 There are 2 main reasons for spinal cord exposure
to radiation—an intentional delivery to treat primary or
secondary lesions or its inevitable inclusion in a radiation ﬁeld
which intends to treat an adjacent neoplasm. In either case,
factors such as total radiation dose, radiation dose per fraction,
time between applications, spinal cord level and associated
chemotherapy affect the incidence and severity of myelop-
athy.52 Radiation myelopathy is divided into the following
4 categories: acute transient radiation myelopathy, acute para-
plegia or quadriplegia, lower motor neuron ﬁndings, and
chronic progressive radiation myelopathy also known as
delayed radiation myelopathy (DRM). DRM is rare but is the
most feared complication and typically occurs after a certain
latent period that ranges from months to few years following
irradiation.26,52
Pathophysiology
The pathogenesis of DRM is likely to be multifactorial with no
single target cell and no single pathway solely responsible.
Damage to vascular endothelial cells,53 direct injury of
oligodendroglia and myelin sheaths,54 and disturbance of the
intra-spinal venous drainage because of lesions in the vein
walls55 have been considered most important.46
It is known that the spinal cord has an enhanced radio-
sensitivity relative to other organs and that there is no uniformly
accepted “spinal cord tolerance” and that no precise threshold
dose is considered safe.56 A total dose of 45 Gywith fractions of
1.8-2 Gy is generally accepted as dose limit using conventional
radiotherapy,57 although 40 Gy poses however a small risk of
myelopathy. Doses of 45 Gy and 52 Gy to the cervical cord
result myelopathy rates of 0.1% and 1% respectively with a
lower incidence in the thoracic cord.48,58 Reports of myelop-
athy after stereotactic radiosurgery to spinal lesions are rare.59
Concomitant chemotherapy is a recognized risk factor for
development of radiation myelopathy. In the past years,
targeted antibody and antireceptor therapies have emerged,
but the extent to which these agents contributed to the
development of radiation myelopathy remains unknown.57
Previous exposure to radiation, particularly less than 2 years,
may also carry an increased risk as spinal cord damage is most
likely to be becomeovert during this period.56 The volume and
length of spinal cord as well as the spinal cord segment
irradiated may also inﬂuence the incidence of radiation
myelopathy.56
Other factors in the patients ' medical history and physical
status make the spinal cord sensitive to radiation injury.
Hypertension, diabetes, autoimmune disease, congenital and
acquired spinal cord abnormalities, pre-existing CNS injury,
elevated hemoglobin, hypotension, alcohol abuse, and infec-
tious disease also enhance the cord 's sensitivity to radiation
damage.60
Clinical Presentations
Overall, 4 clinical syndromes of radiation myelopathy have
been described are as follows: (1) an acute transient radiationpitalar Lisboa Central September 16, 2016.
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Figure 6 Methotrexate myelopathy. Midsagittal (A) and axial (B-D) STIR images in a patient who underwent intrathecal
methotrexate therapy for acute lymphoblastic leukemia. Images show high-signal intensity in dorsal and lateral columns
(arrows) mimicking subacute combined degeneration. STIR, short-tau inversion recovery. (Courtesy: Lazaro Amaral,
Sao Paulo, Brazil.)
J. Ramalho et al.458myelopathy (most common) characterized by Lhermitte 's sign
with no other abnormalities on neurologic examination, (2) an
acutely developing paraplegia or quadriplegia presumably
secondary to ischemia and hemorrhage of the spinal cord
caused by radiation-induced blood vessel damage, (3) a lower
motor neuron disease in the upper or lower extremities,
presumably caused by selective anterior horn-cell damage,
and (4) DRM.52,56,61 Although the second and the third
syndromes are exceedingly rare, the last one is the one most
concerning.
Acute transient radiation myelopathy is a self-limiting
early delayed reaction usually treated with corticosteroids.
It occurs after a latent period of 2-4 months and is
characterized by brief electric-like sensations in the spine
and extremities triggered by neck ﬂexion or extension
(Lhermitte 's sign). Clinical improvement is generally
seen within 2-9 months followed by complete recovery.
There is no correlation between acute transient radiationDownloaded from ClinicalKey.com at Centro Hos
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condition, which may be permanent. It generally occurs
after a latent period of time of 9-18 months but has been
reported up to 3-4 years after completion of radiation
treatment. Various combinations of motor and sensory
deﬁcits occur and depend on the anatomic level of cord
injury. Development of bowel and bladder dysfunctions
may occur. DRM may be fatal if it involves the upper
cervical level.Pathology Findings
Myelinated ﬁbers and blood vessels are the most affected
structures. In chronic progressive radiation myelopathy white
matter necrosis and demyelination with vascular lesions
including stenosis, thrombosis, hemorrhage, ﬁbrinoid vascular
necrosis, and venous wall thickening and hyalinization are
seen.62 There is also gray matter involvement, includingpitalar Lisboa Central September 16, 2016.
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Toxic and metabolic myelopathies 459astrocytosis and hyalinosis of the vessel walls, but neurons are
usually spared.60
Imaging Findings
In acute transient radiationmyelopathyMRI is usually normal.
In DRM, MRI shows cord swelling initially and a long
intramedullary lesion with increased T2 signal and contrast
enhancement (Fig. 7). The MRI ﬁndings correlate with neuro-
logic symptoms. In the chronic stage MRI demonstrates cord
atrophy. Radiation-induced bonemarrow changes indicate the
extension of the irradiated ﬁeld and may help in reaching the
correct diagnosis.
Positron emission tomography-computed tomography
studies might have a role in differentiating radiation myelop-
athy from primary spinal cord lesions and spinal metastases.
However, very few positron emission tomography-computed
tomography studies have been conducted in the spinal cord
and their results need validation.52
Diagnosis
Diagnostic criteria for DRM include—(1) the affected spinal
cord segmentmust be in the irradiated zone, (2) symptomatol-
ogy must correspond to the radiated spinal cord segment,
(3) and the latency period should be more than 6 months.
The differential diagnosis represents a challenging problem.
Metastatic tumor is the most common cause of cord lesions in
oncologic patients presenting with myelopathy.52 PrimaryA B
Figure 7 Radiation therapy-relatedmyelopathy. BrainMRI coron
postcontrast T1-WI (C) of a patient who underwent radiatio
intramedullary area of high-signal intensity on FLAIR (arrows on
gadolinium administration (* on C). FLAIR, ﬂuid attenuation in
Downloaded from ClinicalKey.com at Centro Hos
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ologies presenting with myelopathy must also be ruled out
including paraneoplastic syndrome, zoster myelopathy, and
myelopathy secondary to chemotherapy.52 Nerve conduction
studies show slowing or complete block in spinal conduction.
CSF examination is usually normal but mild elevation of
protein levels and lymphocytosis may be seen.52,63,64Treatment or Prognosis
No treatment has conclusively been shown to be of value in
DRM. Several therapies such as corticosteroids, anticoagula-
tion, pentoxifylline, vitamin E, and hyperbaric oxygen have
been tried with limited beneﬁts. Some patients derive a short-
term beneﬁt from steroids which may be related to decreasing
edema and inﬂammation.52Toxic Myelopathies Associated
With Geographical Predilection
Spinal Sea Stroke
Deﬁnition
Spinal sea stroke is characterized by spinal and brainstem
infarctions that occur in patients swimming in the North
Carolina and Virginia coasts probably caused by contact with
toxic marine animals.C
al FLAIR (A), spineMRImidsagittal T2 (B) andmidsagittal
n therapy. Radiation-induced myelopathy is seen as an
A) andT2-WI (arrows on B)withmild enhancement after
version recovery. (Courtesy: Dr Quaghebeur Oxford, UK.)
pitalar Lisboa Central September 16, 2016.
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J. Ramalho et al.460Pathophysiology
Brainstem and spinal cord strokes in young adults are
extremely rare. Jellyﬁsh toxins have been proposed as a cause
but the mechanism of neural tissue damage is unknown. It is
also unclear why in all of the reported cases the abnormalities
involved only the spinal cord and brainstem but spared the
brain65 Some jellyﬁsh toxins affect the calcium channels of
neurons, a process that could lead to cytotoxic edema, failure
of cellular energetics, and eventually to irreversible damage
such as seen in ischemia. Some authors have postulated that
damage to the spinal cord is not direct but due to systemic
hypotension with subsequent infarctions.65
Clinical Presentations
Patients typically present with an acute severe dysfunction of
sensory and motor systems. Neurologic signs and symptoms
depend on the level of spinal cord involvement and include
severe back pain, loss of sphincter control, paraplegia or
paraparesis, or quadriplegic or tetraplegia in patients with
higher cord lesions.65
Pathology Findings
None of the published cases of spinal sea stroke report
pathology ﬁndings.
Imaging Findings
The hallmark of spinal cord infarction is high T2 signal
intensity in the cord (Fig. 8) especially involving the anterior
two-third of the cord that correspond to the territory supplied
by the anterior spinal artery. Diffusion weighted imaging
shows restricted diffusion of the lesion.
Diagnosis
The diagnosis is generally made clinically. MRI should be
obtained in all patients with suspected spinal cord infarction to
conﬁrm the diagnosis and to exclude other possible treatable
causes of myelopathy.
Treatment or Prognosis
Spinal cord infarctions have a poor prognosis with little chance
of recovery and signiﬁcant sequelae.
Subacute Myelo-Optico Neuropathy
(Clioquinol Toxicity)
Clioquinol (iodochlorhydroxyquin) is an antifungal-
antiprotozoal drug used to treat intestinal parasitic diseases.
Clioquinol 's use has been restricted or discontinued in some
countries because of events in Japan (from 1955-1970) where
more than 10,000 people developed a subacute myelo-optic
neuropathy (SMON). SMON is characterized by subacute
onset of lower limb paresthesias and spastic paraparesis with
optic atrophy. Examination ﬁndings include hyperreﬂexia
and extensor plantar responses. The physiopathology mecha-
nism is unknown but clioquinol is a copper or zinc chelatorDownloaded from ClinicalKey.com at Centro Hos
For personal use only. No other uses without permission. Cand this has led to the speculation that clioquinol-induced
neurotoxicity may be a consequence of copper deﬁ-
ciency.1,26,66-68Lathyrism (India, Bangladesh, and Ethiopia)
and Konzo (Africa)
Lathyrism is a self-limiting neurotoxic disorder endemic in
Bangladesh, India, and Ethiopia, caused by beta-N-oxalyl-
amino-L-alanine, an excitotoxic amino acid present in Lathyrus
sativus.1 Ingestion of this neurotoxin results in increased
intracellular levels of reactive oxygen species and subsequent
impairment of the mitochondrial oxidative phosphorylation
chain. It presents as a subacute or insidious onset spastic
paraparesis. Degeneration is most prominent in motor cortex
and pyramidal tracts that are responsible for lower extremity
function.1
Konzo is a tropical myelopathy seen in Africa resulting
from weeks of high dietary cyanide exposure due to con-
sumption of insufﬁciently processed cassava (Manihot esculenta
Crantz) that contains cyanide. It is characterized by the abrupt
onset of spastic non-progressive paraparesis.69 Years of cassava
consumption have also been implicated in a syndrome of
slowly progressive ataxia, peripheral neuropathy, and optic
atrophy seen in parts of Africa.1,70 The diagnosis is based on a
history of exposure and measurement of serum thiocyanate
levels.
Lathyrism and Konzo are irreversible and non-progressive
conditions. MRI studies are negative. Somatosensory evoked
potentials may show abnormalities which indicate poor
conduction through the spinal cord.26,71 There are no speciﬁc
treatments for these entities.Other Noninfectious and
Noninﬂammatory Myelopathies
Ketoacidosis Myelopathy
Deﬁnition
Myelopathy is a rare complication of diabetic ketoacidosis
characterized by spinal cord edema and infarction usually
associated with cerebral ﬁndings.Pathophysiology
There are no existing explanations for the spinal cord edema
associated with diabetic ketoacidosis probably due its rarity.
Current explanations are limited to diabetic children with
cerebral edema but the pathophysiological mechanisms for
cerebral edema and infarctions are not clear. Systemic hypo-
tension and hypoxia, rapid changes in serum osmolality,
disseminated intravascular coagulation, and thrombosis sec-
ondary to dehydration; hemoconcentration and hyperviscosity
have all been proposed as possible causes.72-75pitalar Lisboa Central September 16, 2016.
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Figure 8 Spinal sea stroke. Sagittal T2-WI at the level of the cervical (A), thoracic (B), and lumbar (C) spine and axial T2-WI
(D) show high T2-WI signal intensity in the anterior two-third of the cord. Sagittal postcontrast fat-suppressed T1-WI
(E and F) show no contrast enhancement in areas of T2 signal abnormality. DWI (G) and ADC map (H) show restricted
diffusion suggesting infarct. ADC, apparent diffusion coefﬁcient.
Toxic and metabolic myelopathies 461Clinical Presentations
Clinical presentation depends on the affected spinal cord level.Pathology Findings
No neuropathologic ﬁndings have been described in
reported cases.Imaging Findings
Cord edema is seen as high T2 signal in the spinal cord usually
associated with cord expansion (Fig. 9). Spinal cord infarction
is seen as areas of bright T2 signal that show restricted
diffusion. Patchy enhancement after gadolinium administra-
tion has been reported. Atrophy may be seen in late stages.Downloaded from ClinicalKey.com at Centro Hos
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Ketoacidosis myelopathy is a diagnostic of exclusion.
Treatment or Prognosis
There is no effective treatment. The prognosis is poor and
varies according with the severity of the disease. Cardiac failure
and pulmonary edema are rare but possible complications in
critically ill patients with diabetic ketoacidosis.75Spinal Cord Decompression Illness
Deﬁnition
Decompression sickness is a clinical syndrome caused by
alterations in environmental pressure resulting in liberation ofpitalar Lisboa Central September 16, 2016.
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J. Ramalho et al.462inert gas bubbles in tissues or blood. Sport divers generally use
compressed air as their breathingmixture and the inert gas that
is liberated during decompression is nitrogen. There are
following 2 types of decompression illness: type I is charac-
terized by joint pain, skin marbling, small patchy hemorrhage,
and lymphatic obstruction and type II is characterized by CNS
involvement. CNS involvement may be further subdivided in
cerebral and spinal cord subtypes. Spinal cord involvement
accounts for 77% of CNS diving injuries. The population at
risk includes, in addition to sport divers, naval and commercial
divers, aviators, astronauts, and compressed air workers.Pathophysiology
The pathophysiological mechanism of spinal cord decom-
pression is not totally understood. Hypotheses include embo-
lization of arterial bubbles via a right-to-left shunt,
development of bubbles within the spinal cord, or emboliza-
tion of the epidural vertebral venous system causing conges-
tion and venous cord infarctions. The last hypothesis is the best
documented one as the alteration of spinal cord venous
draining resulting from the obstruction of the epidural venous
systemhas been shown experimentally.76 Secondary immuno-
inﬂammatory processes may contribute to worsening of
symptoms. Nitrogen bubbles lodge in spinal veins at the
thoracic level; there the spine mobility is restricted by the
rib cage.A B
C
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Figure 9 Ketoacidosis myelopathy. Sagittal (A) and axial (B-D) T
involving the central aspect of the cord (arrows). Sagittal T1-W
contrast enhancement.
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The great majority of spinal cord decompression sickness
results in subjective sensory abnormalities distributed accord-
ing to the dermatomes. A less frequent but more characteristic
presentation corresponds to numbness in the limbs with a
progressive ascending level of both sensory and motor deﬁcits
often accompanied by disturbances of bladder function.77,78Pathology ﬁndings
Spinal cord lesions are scattered throughout the white matter
with no segmental distribution. The dorsolateral white matter
is more vulnerable because of its high fat content in which
nitrogen is readily stored.Imaging Findings
MRI is reliable in the early detection of spinal cord lesions that
occur in decompression accidents leading to prompt hyper-
baric treatment and in the follow-up during and after hyper-
baric recompression. MRI may demonstrate patchy areas of
increased T2 signal intensity in the white matter tracts
(Fig. 10).Diagnosis
The diagnosis relies on clinical history, physical examination,
and MRI ﬁndings.E F
2-WI of thoracic spine show high T2-WI signal intensity
I (E) and postcontrast fat sat T1-WI (F) show areas of
pitalar Lisboa Central September 16, 2016.
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Figure 10 Spinal cord decompression sickness. Axial T2-WI at level of
thoracic spine shows high-signal intensity in the dorsolateral white
matter tracts. The lesions are usually scattered throughout the white
matter with no segmental distribution. (Courtesy: A. Vidal, Santiago,
Chile.)
Toxic and metabolic myelopathies 463Treatment or Prognosis
Hyperbaric oxygen therapy is the treatment of choice as it
reduces the bubble volume and increases concentration of
dissolved oxygen in ischemic tissues. Incomplete recovery is
seen in 20%-30% of patients.79,80 Age, depth, bladder
dysfunction, persistence or worsening of signs before recom-
pression, and a Boussuges score more than 7 are independent
predictive variables for poor clinical recovery.78Surfer 's Myelopathy
Deﬁnition
Surfer 's myelopathy is a rare non-traumatic injury that occurs
in novice surfers who lay prone on a surfboardwith the lumbar
spine hyperextended for prolonged periods of time. It is
probably underdiagnosed and underreported as it is a rare
condition only recently recognized.81
Pathophysiology
The pathophysiology of surfer 's myelopathy is unknown.
Arterial insufﬁciency fromhyperextension of the lumbar spine,
venous hypertension associatedwith obstruction of the inferior
vena cava by the liver whereas lying in a prone position, ﬁbro-
cartilaginous embolism caused by retrograde embolism of the
nucleus pulpous into the radicular spinal cord arteries, or
avulsion of perforating arteries have all been proposed.81,82
Clinical Presentations
Surfer 's myelopathy is usually preceded by back discomfort
followed by acute myelopathy with variable motor-sensory
involvement and urinary incontinence.
Pathology Findings
No deﬁnite histopathologic conﬁrmation has been published,
but surfer 's myelopathy probably is the result of a vascular
phenomenon involving dynamic compression, vasospasm, or
thrombotic infarction of the artery of Adamkiewicz that occursDownloaded from ClinicalKey.com at Centro Hos
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individuals are lying prone on a surfboard.81,82
Imaging Findings
Surfer 's myelopathy is usually associated with a longitudinally
extensive T2 hyperintense central cord lesion in the midthora-
cic region with variable cranial and caudal extension. Patchy
increased T1 signal presumably related to petechial hemor-
rhage have been described.83 Enhancement of the ventral roots
of the cauda equina have also reported.81,82,84,85
Diagnosis
The characteristic clinical history associated with the longitu-
dinally extensive T2 hyperintense spinal cord lesion on MRI
suggests the diagnosis.
Treatment or Prognosis
No treatment is available. Recovery is variable ranging from
complete recovery of function to persistent paraplegia.Conclusion
Toxic and metabolic myelopathies and myeloneuropathies are
relatively rare clinical conditions that share clinical, neuro-
pathologic, and imaging features. Acquaintance with these
entities may lead to accurate diagnosis with successful identi-
ﬁcation of the underlying cause and appropriate treatment
which may revert or prevent progression of symptoms
associated with these incapacitating disorders.
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